Articles By Anuja Singh
BioNextAI Media Report: Keytruda’s Ovarian Cancer Combo Triumph—28% Survival Boost Lifts Merck Stock 4%…
Published by BioNextAI Media – Merck’s KEYTRUDA (pembrolizumab) delivered compelling Phase 3 data from combination regimens in ovarian cancer,…
ByBioNextAI Media Report: Merck’s Gardasil Cuts—$200M Savings, 150 Layoffs Amid 5-10% Demand Drop
Published by BioNextAI Media – In a calculated response to softening markets, Merck is halting production of its HPV…
Merck’s Bold Pivot: Can Dividing Oncology from the Rest Save Keytruda’s Legacy?
Merck’s audacious restructuring of its pharmaceutical operations into standalone oncology and non-oncology divisions isn’t mere corporate tinkering—it’s a…
Lilly’s $2.4B Bet on In Vivo CAR-T: Acquiring Orna Therapeutics to Revolutionize Autoimmune Treatments
Eli Lilly and Company revealed plans in early February 2026 to acquire Orna Therapeutics, a cutting-edge biotech company…
Can Eli Lilly’s Orforglipron Overtake Novo Nordisk’s Rybelsus in the Race for Oral GLP-1…
Indianapolis, Ind., 2026 — Eli Lilly and Company today announced positive head-to-head Phase 3 results demonstrating that its…
Is Bayer’s Lawsuit Against Johnson & Johnson Escalating the Competitive Battle in Prostate Cancer…
Leverkusen, Germany — Bayer AG has filed a lawsuit in U.S. federal court against Johnson & Johnson, alleging…
BioNextAI Media Report: Keytruda’s Ovarian Cancer Combo Triumph—28% Survival Boost Lifts Merck Stock 4%…
Published by BioNextAI Media – Merck’s KEYTRUDA (pembrolizumab) delivered compelling Phase 3 data from combination regimens in ovarian cancer,…
BioNextAI Media Report: Merck’s Gardasil Cuts—$200M Savings, 150 Layoffs Amid 5-10% Demand Drop
Published by BioNextAI Media – In a calculated response to softening markets, Merck is halting production of its HPV…
Merck’s Bold Pivot: Can Dividing Oncology from the Rest Save Keytruda’s Legacy?
Merck’s audacious restructuring of its pharmaceutical operations into standalone oncology and non-oncology divisions isn’t mere corporate tinkering—it’s a…
Lilly’s $2.4B Bet on In Vivo CAR-T: Acquiring Orna Therapeutics to Revolutionize Autoimmune Treatments
Eli Lilly and Company revealed plans in early February 2026 to acquire Orna Therapeutics, a cutting-edge biotech company…
Can Eli Lilly’s Orforglipron Overtake Novo Nordisk’s Rybelsus in the Race for Oral GLP-1…
Indianapolis, Ind., 2026 — Eli Lilly and Company today announced positive head-to-head Phase 3 results demonstrating that its…
Is Bayer’s Lawsuit Against Johnson & Johnson Escalating the Competitive Battle in Prostate Cancer…
Leverkusen, Germany — Bayer AG has filed a lawsuit in U.S. federal court against Johnson & Johnson, alleging…